Methods for treatment of patients with myelodysplastic syndromes
AssigneeActinium Pharmaceuticals, Inc.
InventorMark Berger
Life of this patent
Estimating the term…
Abstract
Methods for treating a proliferative disease in hematologic malignancy in a subject having a complex karyotype by administering an effective amount of an immunotherapy which includes a targeting agent for an epitope of CD33. The proliferative disease may be a hematological disease or disorder such as multiple myeloma, acute myeloid leukemia, myelodysplastic syndrome, and myeloproliferative neoplasm. The effective amount of the anti-CD33 targeting agent may be an amount sufficient to induce myeloconditioning or an amount to induce myeloablation. The methods may further include transplanting allogeneic stem cells to the patient after administration of the anti-CD33 targeting agent.
Claims23
A method of treating a hematologic malignancy in a human subject, comprising administering to the subject an effective amount of an anti-CD33 targeting agent,
- wherein the hematological malignancy has a complex karyotype or a p53 mutation,
- wherein the hematologic malignancy comprises myelodysplastic syndrome (MDS), acute myeloid leukemia (AML), or a combination thereof,
- wherein the anti-CD33 targeting agent comprises lintuzumab, gemtuzumab, or vadastuximab,
- wherein the anti-CD33 targeting agent comprises a radiolabel selected from 225Ac, and
- wherein the effective amount of the anti-CD33 targeting agent comprises a radiation dose of 0.1 to 10 μCi/kg body weight of the subject, and a total protein dose of less than 16 mg/kg body weight of the subject.
Dependencies are inferred from the claim text.